Allspring Global Investments
GLUE icon

Allspring Global Investments’s Monte Rosa Therapeutics GLUE Stock Holding History

Allspring Global Investments’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.54M Sell
352,857
-39,370
-10% -$744K 0.01% 762
2026
Q1 		$6.45M Buy
392,227
+365,272
+1,355% +$6.99M 0.01% 815
2025
Q4 		$423K Buy
26,955
+2,358
+10% +$31.8K ﹤0.01% 1421
2025
Q3 		$182K Buy
+24,597
New +$130K ﹤0.01% 1557
2022
Q2 		– Sell
-13,899
Closed -$194K – 2779
2022
Q1 		$194K Sell
13,899
-1,644
-11% -$22.8K ﹤0.01% 2578
2021
Q4 		$317K Buy
+15,543
New +$325K ﹤0.01% 2480

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Allspring Global Investments's GLUE Position: Q2 2026 in Review

Allspring Global Investments reduced its Monte Rosa Therapeutics (GLUE) stake by 10% in Q2 2026, selling an estimated $744K and leaving 352,857 shares worth $8.54M. The position accounts for 0.01% of the portfolio, ranked #762.

Allspring Global Investments first reported a position in GLUE in Q4 2021 and has held it in 6 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Allspring Global Investments held 352,857 shares of Monte Rosa Therapeutics worth $8.54M as of Q2 2026.
  • Allspring Global Investments sold 39,370 Monte Rosa Therapeutics shares in Q2 2026, an estimated $744K.
  • Monte Rosa Therapeutics made up 0.01% of Allspring Global Investments's portfolio in Q2 2026, its #762 holding.
  • Allspring Global Investments first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.